Business
Tilray® Receives Complete GMP Certification at EU Campus
Licensing expands company’s international export capacity to serve authorized medical cannabis markets Provides authorization to complete medical cannabis
About this update from Tilray Brands, Inc.
[{"type":"text","content":"\nLicensing expands company’s international export capacity to serve authorized medical cannabis markets \n\n\nProvides authorization to complete medical cannabis extraction on-site and the production of bulk extracts to manufacture medical cannabis oil as a finished product \n\n\nCertification signals another milestone for EU campus as Tilray’s international medical cannabis hub \n\n NANAIMO, British Columbia--(BUSINESS WIRE)--\nTilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced its wholly-owned subsidiary Tilray Portugal, Unipessoal Lda. (“Tilray Portugal”) has received a Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its manufacturing facility in Cantanhede, Portugal. The GMP certification was issued by Infarmed, the Portuguese National Authority of Medicines and Health Products which provides end-to-end GMP certification for Tilray’s current operations in Portugal.\n\n\nThis is the third GMP certification for Tilray Portugal, which allows the facility to manufacture medical cannabis extracts in-house and export GMP-produced finished medical cannabis products, both dried flower and oil, from Portugal throughout European Union and other international markets with legal medical cannabis regulations. Further, the additional certification authorizes Tilray to manufacture bulk extracts on-site to sell as cannabis API (active pharmaceutical ingredients) and provides additional quality control lab capacity to further advance the Company’s ability for product innovation and research.\n\n\n“This is an important milestone for our strategic growth in the international medical cannabis market,” says Sascha Mielcarek, Tilray’s Managing Director in Europe. “Our third GMP certification will enable us to manufacture more products at our facility and export a greater range of medical products to international patients, partners and markets. As demand increases around the world and more legal medical cannabis markets emerge, Tilray’s EU campus is ready to serve more partners and patients across the EU and other international medical markets.”\n\n\nTilray has announced the previous license issuances, GMP certifications, and exports:\n\n\n\nInitial licensing and GMP Certification: In May 2019, T...